Policy Reforms Could Make India a Global Pharma Innovation Hub, Says Lilly's Patrik Jonsson
Loading more articles...
Lilly VP: India Can Be Global Pharma Innovation Hub with Policy Reforms
C
CNBC TV18•20-03-2026, 21:04
Lilly VP: India Can Be Global Pharma Innovation Hub with Policy Reforms
•Patrik Jonsson, Executive VP at Eli Lilly International, states India can become a global pharmaceutical innovation hub by strengthening policy frameworks and aligning with global standards.
•Jonsson emphasizes India's strong scientific talent but highlights the need for more predictable and innovation-friendly regulations to unlock its full potential.
•He stresses the importance of stronger intellectual property protection and regulatory data protection, noting that compulsory licensing is a concern and regulatory data protection would attract global investment.
•Lilly is deepening its presence in India with a $1 billion manufacturing investment and expanded operations in Hyderabad and Bengaluru, also exploring AI-led drug discovery with Nvidia.
•Despite India's promise, challenges like regulation, pricing, and generic competition persist, even as companies like Lilly drive innovation in areas such as diabetes and obesity treatment.
